Zhongchao Inc Stock Price, News & Analysis

Zhongchao Inc. (NASDAQ: ZCMD) announced the establishment of Chongqing Xinjiang Pharmaceutical Co., Ltd. to enhance the accessibility and affordability of medications for patients with oncology and other major diseases. This new entity aims to streamline pharmaceutical procurement via a 2B2C platform, collaborating with Zhixun Internet Hospital and others. The initiative is part of Zhongchao's strategy to expand its 'Medical-Pharmaceutical-Patient' model, addressing growing patient-oriented healthcare demands in China. The company seeks to improve drug delivery and patient experience.

Zhongchao Inc. (NASDAQ: ZCMD) announced the launch of its subsidiary Zhixun Internet Hospital in Liaoning, aimed at providing standardized Internet healthcare services for oncology and major diseases. This initiative enhances Zhongchao's patient management capabilities by offering comprehensive services, including remote consultations and follow-up visit management. The All-in-One Service model aims to improve treatment continuity and patient outcomes. Chairman Weiguang Yang emphasized the importance of connecting in-hospital and out-of-hospital services to enhance the quality of medical care.

Zhongchao Inc. (NASDAQ: ZCMD) has announced a strategic shift to expand its business model from 'Medical-Pharmaceutical' to 'Medical-Pharmaceutical-Patient', focusing on oncology and major disease management. The company launched its patient management business in 2021, achieving a 40.4% improvement in Duration of Therapy for liver cancer patients using its self-developed system. Over hundreds of thousands of patients have benefited from disease management services. CEO Weiguang Yang emphasized the commitment to digital innovation in healthcare to enhance patient outcomes and drive shareholder value.

Zhongchao Inc. (NASDAQ: ZCMD) announced the launch of its MDMOOC platform's online training course titled "Disease Prevention and Distribution Quality Management," aimed at enhancing skills in vaccination management for up to 20,000 healthcare staff. The course, launched in April 2022, is accessible through the MDMOOC website and WeChat platforms. Industry experts from various locations will lead the course, addressing key aspects of disease control and public health. Zhongchao remains committed to providing timely training for medical professionals in response to pandemic-related challenges.

Zhongchao Inc. (NASDAQ: ZCMD) reported a 94.6% decline in net income to $238,665 for the fiscal year 2021, down from $4.46 million in 2020. Revenues fell 9.4% to $16.30 million, primarily due to reduced income from medical training and education services. Gross profit also decreased by 20.5% to $9.44 million, leading to a gross margin decline of 8.1 percentage points. Operating expenses rose 32.2% to $9.76 million, driven by significantly increased general and administrative costs.

Zhongchao Inc. (NASDAQ: ZCMD) announced that its innovative patient management system has significantly improved the Duration of Therapy (DOT) by 40.4% for liver cancer patients. This improvement enhances drug efficiency and supports longer patient survival rates. The system aids nearly 20,000 patients in managing their treatment through education, follow-ups, and psychological support. With 400,000 new liver cancer cases reported in China in 2020, this advancement has the potential to notably impact patient outcomes and overall healthcare efficiency.

Zhongchao Inc. (NASDAQ: ZCMD) has launched the Hematology MDT Platform, an online training resource designed to enhance multidisciplinary treatment (MDT) skills for healthcare professionals. This platform facilitates real-time collaboration and problem-solving among physicians by providing access to expert guidance and training videos. As of August 2021, over 10,000 physicians have engaged with this platform, highlighting the growing demand for MDT in treating complex diseases like hematology within China. The company aims to expand this model across other medical areas to improve healthcare efficiency.

Zhongchao Inc. (NASDAQ: ZCMD) announced the launch of its Hematological Tumor Patient Care Center via its subsidiary, Shanghai Zhongxin Medical Technology. This initiative expands its services in tumor patient management to the out-of-hospital market, catering to nearly 10,000 hematological tumor patients. The Care Center provides comprehensive disease management, including patient education and personalized health assessments. With a projected rise in hematologic tumor cases in China, Zhongchao aims to enhance treatment experiences for patients through its innovative management services.

Zhongchao Inc. (NASDAQ: ZCMD) has expanded its patient management services for ovarian cancer through its subsidiary, Shanghai Zhongxin Medical Technology. This follows the Zeyoulexiang Patient Assistance Project, which aids patients requiring Niraparib. Utilizing their All-in-One System, over 5,000 patients have benefited since July 2021. The ovarian cancer market is projected to grow significantly, from $1.8 billion in 2018 to $6.7 billion by 2028. Zhongchao aims to capitalize on this growth by enhancing treatment outcomes and expanding its patient management operations.